Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
Scientific Advisory Board Roundtable: Current Developments and New Directions Discussed
![[Image: transparent.gif]](http://www.alsconsortium.org/images/transparent.gif)
Scientific Advisory Board Roundtable: Current Developments and New Directions Discussed
http://www.alsconsortium.org/news_sab_2013.php
March 8th, 2013
The NEALS Scientific Advisory Board (SAB) convened in Boston, MA this past February to brainstorm new directions for the field of ALS research and to review current scientific developments.
Fifteen researchers from academic institutions, ALS foundations, and biopharmaceutical companies attended the meeting which was led by NEALS SAB Co-Chairs, Robert Brown, DPhil, MD (University of Massachusetts) and Jeffery Rothstein, MD, PhD (Johns Hopkins).
The objective of the round-table discussion was to evaluate potential therapies for the treatment of ALS and UMND, including assessing ready and near-ready therapeutic candidates for future clinical trials and reviewing ongoing NEALS trials. The meeting built upon work completed at last year's round-table discussion and expanded the list of compounds of interest to NEALS.
The SAB is responsible for advising the NEALS Executive Committee and NEALS members about the scientific basis of NEALS research activities. This includes but is not limited to the development, conduct, analysis, and publication of NEALS trials. The SAB meets quarterly.
Scientific Advisory Board Roundtable: Current Developments and New Directions Discussedhttp://www.alsconsortium.org/news_sab_2013.php
March 8th, 2013
The NEALS Scientific Advisory Board (SAB) convened in Boston, MA this past February to brainstorm new directions for the field of ALS research and to review current scientific developments.
Fifteen researchers from academic institutions, ALS foundations, and biopharmaceutical companies attended the meeting which was led by NEALS SAB Co-Chairs, Robert Brown, DPhil, MD (University of Massachusetts) and Jeffery Rothstein, MD, PhD (Johns Hopkins).
The objective of the round-table discussion was to evaluate potential therapies for the treatment of ALS and UMND, including assessing ready and near-ready therapeutic candidates for future clinical trials and reviewing ongoing NEALS trials. The meeting built upon work completed at last year's round-table discussion and expanded the list of compounds of interest to NEALS.
The SAB is responsible for advising the NEALS Executive Committee and NEALS members about the scientific basis of NEALS research activities. This includes but is not limited to the development, conduct, analysis, and publication of NEALS trials. The SAB meets quarterly.